Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. - Wikidata - awgldk - TriplyDB

Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.

Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.

http://www.wikidata.org/entity/Q33202542

about

Pharmacological interventions for pain in children and adolescents with life-limiting conditions Bisphosphonate therapy for osteogenesis imperfecta Bisphosphonate therapy for osteogenesis imperfecta Calcium supplementation for improving bone mineral density in children Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges Recognizing and treating secondary osteoporosis The management of osteoporosis in children.Managing the patient with osteogenesis imperfecta: a multidisciplinary approach.Bisphosphonate treatment for children with disabling conditions.The ever-expanding conundrum of primary osteoporosis: aetiopathogenesis, diagnosis, and treatment.The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.Current and emerging treatments for the management of osteogenesis imperfecta.Fractures in myelomeningocele.RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta.Molecular, phenotypic aspects and therapeutic horizons of rare genetic bone disorders.Bisphosphonate therapy for osteogenesis imperfecta.Decrease in outpatient department visits and operative interventions due to bisphosphonates in children with osteogenesis imperfecta.Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment Bisphosphonate treatment of bone disease Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta--a case report.Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.Ginsenoside Rg1 promotes osteogenic differentiation of rBMSCs and healing of rat tibial fractures through regulation of GR-dependent BMP-2/SMAD signaling.Management pitfalls of fractured neck of femur in osteogenesis imperfecta Treatment of osteogenesis imperfecta: who, why, what?Bone mineral density in developing children with osteogenesis imperfecta: a longitudinal study with 9 years of follow-up.Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta.Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition.Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.Optimization of Bone Health in Children before and after Renal Transplantation: Current Perspectives and Future Directions.Quality of life in children and adolescents with Osteogenesis Imperfecta: a qualitative interview based study.Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta New perspectives on osteogenesis imperfecta Measures of self-care independence for children with osteochondrodysplasia: a clinimetric review.Osteogenesis imperfecta: diagnosis and treatment.Femoral neck fractures in osteogenesis imperfecta treated with bisphosphonates.Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.

P2860

Q24187283-93276D00-9276-47A1-BC57-40AF8EB2F62A Q24194821-A7726178-FEEA-4689-AB95-4F3D0695AA39 Q24240782-4AF14669-849D-422D-A399-272CEA35DE0C Q24246305-C121F015-5958-4428-9C28-FE7550FF52D6 Q26744599-B9853468-7268-4741-82BD-6609645616BD Q28270738-EE76DFA3-78A5-4721-9E31-511219381FDB Q30251490-B4B129DF-57F2-40A6-A185-99E4AC993C77 Q33554034-F2D80CCC-76F7-4E67-8FE4-AA15C6D0E35F Q33680621-E8A50C22-644F-4476-B04E-C2EE3BA95F64 Q33781943-120A852C-474E-4FAD-9B5A-7A1DF745AB54 Q33847609-E569A018-32EC-4C23-B04D-F3A816918F20 Q34039676-6964BB96-D0EB-4757-A703-E9B4827ABA44 Q34133308-5A65C1D5-3BE4-416C-B5FA-3842B4B7CA94 Q34166648-C7BC868E-2FAD-433C-94CF-1BDAB7F831C0 Q34234347-8B65EE05-0B2D-4C93-9C80-EAAFA1E43EA7 Q34502398-CBE39F1B-B65F-427A-9A73-6C0222B9EFA5 Q34543060-0A904F3E-7B00-4850-863D-9B29278B1F1B Q34678492-9036CC10-9E23-4A02-A9BB-67A84B5DC096 Q34759279-AE725FC7-4710-44C9-B7F0-39135BD25FEB Q35283631-78AB6CD3-1A30-48C9-8B4A-77A05A760F31 Q35828143-C0E12924-573C-484C-ADB6-428825F12401 Q36153306-EC9317E0-194A-45EF-8FA3-B97D46AC5371 Q36368632-6C25B6BF-5686-4E3D-A6D5-ADD1E7AC9699 Q36472781-B4B2CCF7-2A28-43F0-BF5C-849C6F217CE6 Q36864808-6EF7CA74-346C-428B-8B9F-62EB23CF4657 Q36902343-41892542-6227-4548-8958-4F15F749810C Q37050007-9BEFFB74-9696-4F2E-B033-F49D3BD71292 Q37158425-9D1E8B9E-D65A-4258-BDCD-F7B3B0CBEF3C Q37166804-2E3709D8-5991-46E4-83C9-04743CD9C27C Q37167038-C95E5C94-7B06-4464-BC02-29A980EBC2C0 Q37522199-47742B4A-F922-4B15-9097-5C7C70B4F9CE Q37579579-BD6C6107-9C9F-41C0-89ED-2EA453572297 Q37598894-FA79FD2E-90E0-4D0A-9C96-CD69A4E93CD7 Q37717395-229DA1D0-7437-4F68-8066-D8C543894915 Q37722288-80711187-F9A9-40A3-ADE7-582AE105BDD6 Q37889113-DDF15096-90F0-4F18-A1D0-5EC804C6D1FB Q37897576-34E9CEF8-6A17-425F-AAA5-0850ADCDFA5A Q38223208-869635EA-7D39-4FB9-A0A7-1464EE6DB9A1 Q38615041-4D639F7A-847D-4077-9CB5-D4CB3864B9C3 Q38617388-8035A747-5334-4E3E-B658-A23C573E6CE7

P2860

Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.

http://www.wikidata.org/entity/Q33202542

description

2004 nî lūn-bûn

@nan

2004 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Skeletal effects and functiona ...... ised placebo-controlled study.

@ast

Skeletal effects and functiona ...... ised placebo-controlled study.

@en

type

label

Skeletal effects and functiona ...... ised placebo-controlled study.

@ast

Skeletal effects and functiona ...... ised placebo-controlled study.

@en

prefLabel

Skeletal effects and functiona ...... ised placebo-controlled study.

@ast

Skeletal effects and functiona ...... ised placebo-controlled study.

@en

P1433

Q33202542-586D2193-0349-445B-AFA5-56650AC77C5F

P1476

Q33202542-BE6440CB-564C-451A-942C-5355AC802B1A

P2093

Q33202542-0197CFF3-1A30-4839-BEFE-1B6D638549E7

Q33202542-057785F0-94A0-474B-B701-6C1F83A4BDC8

Q33202542-0CC4E09C-8B61-4B3D-B237-BD4D98E40665

Q33202542-253F7E24-1383-4697-9AD0-13FBD4757539

Q33202542-6FA3631F-F7B4-4A06-A5DE-D54C0C9299E0

Q33202542-94ED4F38-FE53-443B-8A75-E3780DC80BEE

Q33202542-AA2E9FEF-52CD-459F-878C-99A92AB8C3C9

Q33202542-C4E99581-38C0-4CF8-967B-3EED91203A2F

Q33202542-E2232EC0-3CA3-4EC7-9046-D6F56846B4DD

P304

Q33202542-1C4A07C9-4376-4130-8E35-9B78DAD5E56F

P31

Q33202542-74E16841-DD38-486A-A48C-C2CA58C509C3

P356

Q33202542-7CC66AB4-EEBF-4A02-81EF-08AFAA22A5AB

P407

Q33202542-853E4B5C-2F40-4F9E-B608-20AB764D5066

P433

Q33202542-340A50CB-9C5F-44F1-B283-ECF908531E55

P478

Q33202542-88ADE7E7-CC1B-4254-95C4-808B83D96497

P577

Q33202542-0CC4B0E0-242A-4C3D-8E10-D939688E2AC3

P698

Q33202542-FF991F88-C0C5-484A-8D00-F607290D4911

P921

Q33202542-A4AE748E-79F9-4F06-BE23-E8576B768F95

Q33202542-D97F5F77-AE8D-422B-A8AC-4E60D7FC5B38

P356

S0140-6736(04)16101-1

P1433

P1476

Skeletal effects and functiona ...... ised placebo-controlled study.

@en

P2093

Ab Verbout

http://www.w3.org/2001/XMLSchema#string

Alice van Dongen

http://www.w3.org/2001/XMLSchema#string

Cuno Uiterwaal

http://www.w3.org/2001/XMLSchema#string

Dave Schweitzer

http://www.w3.org/2001/XMLSchema#string

Dieke Kok

http://www.w3.org/2001/XMLSchema#string

Hans Pruijs

http://www.w3.org/2001/XMLSchema#string

Maarten Jansen

http://www.w3.org/2001/XMLSchema#string

Ralph Sakkers

http://www.w3.org/2001/XMLSchema#string

Raoul Engelbert

http://www.w3.org/2001/XMLSchema#string

P304

1427-1431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(04)16101-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

9419

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15121405

http://www.w3.org/2001/XMLSchema#string

P921

osteogenesis imperfecta